Cyclic Peptide Compounds for Selective KRAS Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective cyclic compounds that selectively inhibit KRAS over HRAS and NRAS, and there is a need for drug-like peptides that can target RAS-mutant cancer cells.
Innovation Solution
Development of cyclic compounds represented by formula (1) that selectively interact with KRAS and inhibit the growth of tumor cells with RAS mutations, including specific non-natural amino acid-containing peptides such as PP1574, PP1650, and others, which are designed to target KRAS while minimizing interaction with HRAS and NRAS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclic compounds are designed to inhibit RAS proteins, then antitumor effect on RAS-mutant cancer is achieved, but selective inhibition of KRAS over HRAS and NRAS is insufficient
Solution Approach 1:
The patent applies local quality by designing specific amino acid residues at key positions (e.g., position 3 with Arg, position 7 with Lys or Arg, position 11 with Asp or Glu) to create localized interaction zones that selectively recognize and bind to specific residues in the KRAS switch region (Q61, G12, G13), thereby achieving selective inhibition of KRAS while minimizing binding to HRAS and NRAS
Solution Approach 2:
The patent employs asymmetry by creating an asymmetric cyclic peptide structure with specific stereochemistry (L-amino acids in defined configurations) and non-symmetric side chain arrangements that complement the asymmetric binding interface of KRAS, enabling selective recognition of KRAS's unique structural features compared to HRAS and NRAS
2Ease of operation
If medium sized molecules are used to target protein-protein interaction, then cell migration capability is improved, but molecular weight increases beyond low molecular weight compounds
Solution Approach 1:
The patent applies parameter changes by carefully controlling the molecular weight of the cyclic compound to fall within the medium-sized molecule range (500-2000 g/mol), optimizing the balance between cell penetration capability and protein-protein interaction targeting efficacy, while adjusting amino acid composition and cyclic structure to achieve desired pharmacokinetic properties
3Reliability
If cyclic peptide structure is adopted, then membrane permeability and metabolic stability are improved, but drug-likeness requirements become more stringent
Solution Approach 1:
The patent applies segmentation by dividing the cyclic peptide into functional modules: a cyclic core structure for stability, specific amino acid residues for KRAS binding (positions 3, 7, 11), and optional side chain modifications for pharmacokinetic optimization, allowing systematic design that meets drug-likeness criteria while maintaining metabolic stability
Solution Approach 2:
The patent employs composite materials by incorporating non-natural amino acids with specific properties (e.g., enhanced metabolic stability, improved membrane permeability) into the cyclic peptide structure, creating a composite molecular system that combines the advantages of natural amino acids (binding specificity) with engineered properties (stability, permeability)
Data Source
AI summary
Cyclic compounds that selectively inhibit KRAS were found. Moreover, cyclic compounds were found to interact with an amino acid residue specific to KRAS.